Avanos Medical Q2 2024 Adj. EPS $0.34 Beats $0.29 Estimate, Sales $171.700M Beat $170.667M Estimate
Portfolio Pulse from Benzinga Newsdesk
Avanos Medical (NYSE:AVNS) reported Q2 2024 earnings of $0.34 per share, beating the analyst estimate of $0.29. Sales were $171.7 million, also surpassing the $170.667 million estimate. This represents a 41.67% increase in EPS and a 1.36% increase in sales year-over-year.
July 31, 2024 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avanos Medical reported strong Q2 2024 earnings, with EPS of $0.34 beating estimates by 17.24% and sales of $171.7 million surpassing expectations. This indicates robust financial performance and growth.
The significant beat on both EPS and sales estimates, along with strong year-over-year growth, suggests positive investor sentiment and potential short-term stock price appreciation for Avanos Medical.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100